Resmed Inc (NYSE: RMD) has recently enjoyed extremely meaningful positive changes in investment behavior: positive upside/downside volume developed, and the stock’s recent price rise disrupted its longer term downtrend.
Significant positive changes in fundamentals have recently occurred for Resmed Inc (NYSE: RMD): the consensus estimate for June, 2026 increased significantly, and the consensus estimate for June, 2025 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to exceed the cost of capital, RMD is expected to continue to be a modest Value Builder.
Resmed has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Resmed has a poor Appreciation Score of 20 but a good Power Rating of 74, resulting in the Low Neutral Value Trend Rating.
Recent Price Action
Resmed Inc (NYSE: RMD) stock closed at $252.92 on 9/11/24 after a slight gain of 0.02%. However, trading volume in this advance was below average at 68% of normal. The stock has risen 3.3% during the last week and has been exceptionally strong relative to the market over the last nine months.
Be the first to comment